Pilot study for a Brain-Muscle-Computer Interface using the Extensor Pollicis Longus with preselected frequency bands.

We are developing a new class of Brain-Computer Interface that we call a Brain-Muscle-Computer Interface, in which surface electromyography (sEMG) recordings from a single muscle site are used to control the movement of a cursor. Previous work in our laboratory has established that subjects can learn to navigate a cursor to targets by manipulating the sEMG from a head muscle (the Auricularis Superior). Subjects achieved two-dimensional control of the cursor by simultaneously regulating the power in two frequency bands that were chosen to suit the individuals. The purposes of the current pilot study were to investigate (i) subjects' abilities to manipulate power in separate frequency bands in other muscles of the body and (ii) whether subjects can adapt to preselected frequency bands. We report pilot study data suggesting that subjects can learn to perform cursor-to-target tasks on a mobile phone by contracting the Extensor Pollicis Longus (a muscle located on the wrist) using frequency bands that are the same for every individual. After the completion of a short training protocol of less than 30 minutes, three subjects achieved 83%, 60% and 60% accuracies (with mean time-to-targets of 3.4 s, 1.4 s and 2.7 s respectively). All three subjects improved their performance, and two subjects decreased their time-to-targets following training. These results suggest that subjects may be able to use the Extensor Pollicis Longus to control the BMCI and adapt to preselected frequency bands. Further testing will more conclusively investigate these preliminary findings.

Lumpectomy and breast radiotherapy in breast cancer patients with a family history of breast cancer, ovarian cancer, or both.

This article presents an outcomes review of breast cancer patients identified from the cancer registries of four area hospitals. These patients had family histories of breast cancer, ovarian carcinoma, or both and were treated with conservative surgery and radiation to the involved breast. Patients were as follows: group 1, one first-degree relative ( n = 165, one synchronous bilateral breast cancer); group 2, > or =2 first-degree relatives ( n = 21); group 3, one second-degree relative ( n = 20); and group 4, > or =2 second-degree relatives ( n = 18). The total of patients and breast cancer events was 224 and 225, respectively. Group 5 was a subgroup of 53 patients with a substantial risk (>10%) of a BRCA1 or BRCA2 mutation. After a median follow-up of 3.9 years, 5 patients had local failure (2%), and 5 developed a contralateral breast cancer (2%). There were no significant differences in local failure rates between groups (p = 1.0): group 1, 5 of 166 (3%); group 2, 0 of 21 (0%); group 3, 0 of 20 (0%); and group 4, 0 of 18 (0%). Local failure for group 5 was 2% (1 of 53). Four of 143 patients (3%) with a minimum 3 years of follow-up (median, 5.6 years) had local failure, and 5 (4%) developed a contralateral breast cancer. A univariate analysis was statistically significant for differentiation only (well, 0 of 67; moderately, 1 of 57 [1.8%]; poor, 3 of 26 [11.5%], p = 0.008). Overall survival for groups 1-4 did not differ significantly. Although follow-up has been relatively short, we have not found that breast cancer patients with various degrees of family histories of breast/ovarian carcinoma have had a detrimental outcome when treated with conservative therapy.